Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 10/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27973093 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| Bromide SCHEMBL28011619 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| Bromide SCHEMBL28088878 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| Bromide SCHEMBL9575762 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL6727148 | 0.97 | SLC22A1 (0.55) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL3802276 | 0.97 | SLC22A1 (0.55) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL8558471 | 0.97 | SLC22A1 (0.55) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL9575954 | 0.97 | SLC22A1 (0.55) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL11034134 | 0.97 | SLC22A1 (0.55) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL10820897 | 0.97 | SLC22A1 (0.55) | ALDH1A1TP53CYP3A4ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108570281-A | A kind of bi-component modified aqueous polyurethane flame-retardant coatings glue and preparation method thereof | 华南理工大学 | 2018-09-25 | — | — | CN | claimed |
| US-6503945-B2 | Nontoxic, drug delivery, gene therapy; therapy of cystic fibrosis | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2003-01-07 | — | — | US | claimed |
| US-20020077366-A1 | Novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2002-06-20 | — | — | US | claimed |
| US-6346516-B1 | DRUG DELIVERY OF (QUATERNARY) AMINE SALT AND MACROMOLECULE; GENE THERAPY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2002-02-12 | — | — | US | claimed |
| US-12497437-B2 | Modified Mullerian Inhibiting Substance (MIS) proteins and uses thereof for the treatment of diseases | THE GENERAL HOSPITAL CORPORATION | 2025-12-16 | — | — | US | disclosed |
| US-20250346632-A1 | SERPIN PEPTIDES AND METHODS OF USING THE SAME | SERPIN PHARMA LLC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12398179-B2 | Nanomolar peptides and derivatives to differentially modulate ephrin receptors | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250228922-A1 | METHODS FOR TREATMENT OF DISEASES | SERPIN PHARMA, LLC | 2025-07-17 | — | — | US | disclosed |
| US-12357675-B2 | Efficient protein expression in vivo using modified RNA (mod-RNA) | THE GENERAL HOSPITAL CORPORATION | 2025-07-15 | — | — | US | disclosed |
| WO-2025105506-A1 | NUCLEIC ACID, DRUG COMPOSITION, AND METHOD OF PRODUCING NUCLEIC ACID | アンジェス株式会社 | 2025-05-22 | — | — | WO | disclosed |
| US-12291581-B2 | Serpin peptides and methods of using the same | SERPIN PHARMA, LLC (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2025038951-A1 | METHODS AND COMPOSITIONS FOR INTEGRATION OF RNA INTO A DNA GENOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-1190086-A2 | GENETIC MODIFICATION OF MALE GERM CELLS FOR GENERATION OF TRANSGENIC SPECIES AND GENETIC THERAPIES | Cedars-Sinai Medical Center (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6346516-B1 | DRUG DELIVERY OF (QUATERNARY) AMINE SALT AND MACROMOLECULE; GENE THERAPY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2002-02-12 | — | — | US | disclosed |
| US-6333433-B1 | COUPLING ALIPHATIC ALDEHYDE WITH ALKYLAMINE, REDUCING IMINE TO SECONDARY AMINE, REACTING WITH PROTECTED HYDROXYALKYL HALIDE, DEPROTECTING, QUATERNIZING N-HYDROXYALKYL GROUP CONTAINING TERTIARY AMINE WITH ALKYL HALIDE OR TOSYLATE IN POLAR SOLVENT | COUNCIL OF SCIENTIFIC INDUSTRIAL RESEARCH (IN) | 2001-12-25 | — | — | US | disclosed |
| WO-2001087935-A2 | METHODS OF MODULATING ANGIOGENESIS BY REGULATING THE EXPRESSION OF PITUITARY TUMOR TRANSFORMING GENE (PTTG) | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087934-A2 | TREATMENT OF NEOPLASIA/TRANSFORMATION USING A PITUITARY TUMOR TRANSFORMING GENE CARBOXY TERMINAL PEPTIDES | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001088116-A2 | METHOD OF MODULATING ACTIVATION OF LYMPHOCYTES VIA MODULATION OF PITUITARY TUMOR TRANSFORMING GENE, RELATED SCREEINING METHODS | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087039-A2 | TREATMENT OF NEOPLASIA / TRANSFORMATION USING PITUITARY TUMOR TRANSFORMING GENE 2 | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2000069257-A2 | GENETIC MODIFICATION OF MALE GERM CELLS FOR GENERATION OF TRANSGENIC SPECIES AND GENETIC THERAPIES | CEDARS-SINAI MEDICAL CENTER (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077366-A1 | Novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules | NPC1L1, ABCB4, ANXA1 | ALDH1A1 3509/4885TP53 1078/4885CYP3A4 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.